Loading
Folate receptor alpha is a vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab. This dossier gathers the 7 products (2 approved), 26 trials, 0 pathways and 1 resistance route in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
GPI-anchored folate transporter; limited to apical surfaces in normal kidney, lung, and choroid plexus.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | 70-80% | Adenocarcinoma, any expression | Wikipedia | |
| Endometrial cancer | 60-80% | IHC, any expression | Wikipedia | |
| Ovarian cancer | 35-40% | FRα-high (PS2+ in >=75% of cells) | MIRASOL eligibility; ~80% any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Phase 3 | Phase 2 |
|---|---|---|---|
| ADC 5 | |||
| Imaging agent 1 | - | - | |
| Small molecule 1 | - | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
MIRASOL / GOG-3045 NCT04209855 | 3 | Positive | Platinum-resistant ovarian cancer with high folate receptor alpha expression, 1-3 prior lines: mirvetuximab soravtansine vs chemotherapy | OS 16.46 vs 12.75 months (HR 0.67). | |
SORAYA NCT04296890 | 3 | Positive | Platinum-resistant high-grade serous ovarian cancer with high folate receptor alpha expression after one to three prior regimens including bevacizumab: single-arm mirvetuximab soravtansine | Objective responses in about a third of patients with folate receptor alpha-high platinum-resistant ovarian cancer; accelerated approval in November 2022. | |
| 3 | Recruiting | FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer | - | ||
| 3 | Recruiting | A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer | - | ||
| 3 | Recruiting | A Multi-center, Double-blind, Randomized Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | - | ||
| 3 | Completed | A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules | - | ||
| 3 | Recruiting | A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy | - | ||
| 3 | Recruiting | A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC) | - | ||
| 3 | Recruiting | A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer | - | ||
| 3 | Active | A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer | - | ||
| 2/3 | - | REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) | - | ||
| 2 | Recruiting | An Open-label , Multicenter, Multicohort, Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6041 Combination Therapy for Recurrent Ovarian Cancer | - | ||
| 2 | Active | A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | - | ||
| 2 | Recruiting | A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment | - | ||
| 2 | Recruiting | A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer | - | ||
| 2 | Recruiting | A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | - | ||
| 2 | Completed | An Investigator Sponsored Study to Investigate the Safety and Efficacy of CYTALUX™ (PAFOLACIANINE) INJECTION for the Intraoperative Imaging of Prostate Cancer | - | ||
| 2 | Active | A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy. Supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967 | - | ||
| 2 | Active | Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy | - | ||
| 2 | Planned | An Umbrella Clinical Trial of Antibody/Peptide-Drug Conjugates Matched by Mass Spectrometry-Based Absolute Quantitation of Proteins in Locally Advanced or Metastatic Pancreatic or Breast Cancer | - | ||
| 2 | Recruiting | Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer. | - | ||
| 2 | Recruiting | A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer | - | ||
| 1/2 | Active | A Phase 1/2 Open-label Study to Evaluate The Safety, Tolerability, Efficacy And Pharmacokinetics of Mirvetuximab Soravtansine (TAK-853) in Japanese Patients With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | - | ||
RAINFOL-01 (Rina-S) NCT05579366 | 1/2 | Active | Advanced ovarian and endometrial cancer, heavily pretreated: rinatabart sesutecan (FRα ADC, exatecan payload) across FRα expression levels | ORR 55.6% (ovarian, 120 mg/m²); 50% (endometrial, 100 mg/m²). | |
| 1/2 | Recruiting | A Multicenter, Open-label, Dose-escalation and Dose-expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Antitumor Activity of SYS6041 in Patients With Advanced Solid Tumors | - | ||
| 1/2 | Recruiting | A Phase 1/2, Open-Label, Biomarker-Assigned Study of Dual-Targeting CAR-NK Cells Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα/FOLR1), and/or MUC16 (CA125) in Patients With Recurrent or Refractory High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | - | - |
Secondary mutations restore the open reading frame and homologous recombination; also confers platinum resistance.
No pathway diagram carries this target as a node.
| Assay | Platform | Cut-off | Gates |
|---|---|---|---|
| VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Roche Diagnostics · FDA CDx 2022 | IHC | At least 75% of viable tumour cells with membrane staining of at least 2+ intensity (mirvetuximab soravtansine, ovarian cancer) |
No model entry for this target yet; check the cancer entries on the models page.
Why unresolved. MIRASOL enrolled only FRalpha-high platinum-resistant patients; newer FRalpha ADCs with topoisomerase payloads (rinatabart sesutecan, luveltamab tazevibulin) claim activity at lower expression but lack randomised data.
What would answer it. Randomised trials in FRalpha-medium and platinum-sensitive populations with a standardised FRalpha assay.
Query for this target: (TITLE:"Folate receptor alpha" OR ABSTRACT:"Folate receptor alpha" OR TITLE:"FOLR1" OR ABSTRACT:"FOLR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Folate receptor alpha, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/folr1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/folr1.json. Licence CC BY-NC 4.0.